Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Cancer[TA])
50,604 results
  • Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. [Journal Article]
  • BCBMC Cancer 2018 Feb 17; 18(1):194
  • Pulido M, Roubaud G, … Houédé N
  • CONCLUSIONS: While the positivity of this trial indicates a potential benefit of temsirolimus for a subset of bladder cancer patients who are refractory to first line platinum-based chemotherapy, the risk of adverse events associated with the use of this mTOR inhibitor would need to be considered when such an option is envisaged in this frail population of patients. It also remains to identify patients who will benefit the most from this targeted therapy.
  • In vitro and in silico validation of CA3 and FHL1 downregulation in oral cancer. [Journal Article]
  • BCBMC Cancer 2018 Feb 17; 18(1):193
  • Pereira CM, de Carvalho AC, … Carvalho AL
  • CONCLUSIONS: These results showed that the downregulation of CA3 and FHL1 data observed in the ORESTES libraries was validated in HNSCC cell lines and OSCC samples and in a large cohort of samples from the TCGA database. Moreover, it suggests that expression of CA3 and FHL1 could probably be regulated by methylation having an important role the oral carcinogenesis.
New Search Next